Page 6 - புதியது மாறுபாடு மதிப்பீடு நடைமேடை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Virginia Mayo/AP/Shutterstock Vaccines from Johnson & Johnson and Novavax report positive trial results A coronavirus vaccine developed by the US firm Novavax has been shown to be 89 per cent effective in preventing covid-19 in clinical trials. The trials included participants in the UK and South Africa, and found the vaccine to be 86 per cent effective against the UK variant of the virus, but only 60 per cent effective against the variant in South Africa. Novavax said it will immediately begin development on a vaccine specifically targeted to the South African variant. Advertisement Janssen, a subsidiary of US firm Johnson & Johnson, announced that its covid-19 vaccine showed 66 per cent efficacy in an international trial. These results are based on a single dose of the vaccine, which makes it easier to administer than the two-shot vaccines that have already been approved. The company has said it will sell its vaccine on a not-for-profit basis.

New yorkUnited statesUnited kingdomEast sussexSouth carolinaLos angeles countyTamil naduLos angelesSouth africaNorthern irelandCity ofTower hamletsPrincess royalHaywards heathWest sussexNewcastle upon tyne